

# Marco Sgarbanti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2602009/publications.pdf>

Version: 2024-02-01

35  
papers

1,035  
citations

471061

17  
h-index

414034

32  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Type I Interferons in COVID-19 Pathogenesis. <i>Biology</i> , 2021, 10, 829.	1.3	32
2	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. <i>Journal of Virology</i> , 2021, 95, e0135821.	1.5	13
3	Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. <i>Pathogens</i> , 2021, 10, 1488.	1.2	5
4	Fighting HIV-1 Persistence: At the Crossroads of $\alpha$ -Shoc-K and B-Lox. <i>Pathogens</i> , 2021, 10, 1517.	1.2	12
5	$\text{I}\beta$ kinase- $\mu$ -mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. <i>Neoplasia</i> , 2020, 22, 459-469.	2.3	8
6	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. <i>Journal of Virology</i> , 2019, 93, .	1.5	16
7	Alternate NF- $\text{I}\beta$ -Independent Signaling Reactivation of Latent HIV-1 Provirus. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
8	A model of the three-dimensional structure of human interferon responsive factor 1 and its modifications upon phosphorylation or phosphorylation-mimicking mutations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 4632-4643.	2.0	0
9	Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling. <i>Viruses</i> , 2018, 10, 98.	1.5	17
10	IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 414-432.	0.5	18
11	HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation. <i>MBio</i> , 2016, 7, .	1.8	19
12	Type I IFN $\alpha$ – A blunt spear in fighting HIV-1 infection. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 143-158.	3.2	22
13	HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies. <i>Viruses</i> , 2014, 6, 1715-1758.	1.5	61
14	$\text{I}\beta$ Kinase $\mu$ Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes. <i>Molecular and Cellular Biology</i> , 2014, 34, 1054-1065.	1.1	33
15	Therapeutics for HIV-1 reactivation from latency. <i>Current Opinion in Virology</i> , 2013, 3, 394-401.	2.6	30
16	IRF-7: an antiviral factor and beyond. <i>Future Virology</i> , 2013, 8, 1007-1020.	0.9	3
17	HIV-1, interferon and the interferon regulatory factor system: An interplay between induction, antiviral responses and viral evasion. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 255-270.	3.2	38
18	The development of immune-modulating compounds to disrupt HIV latency. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 159-172.	3.2	17

#	ARTICLE	IF	CITATIONS
19	CS03-5. IRF-1 phosphorylation by I-kappa-B kinase epsilon impairs IFN beta stimulation in activated CD4+ T cells.. Cytokine, 2011, 56, 9.	1.4	0
20	The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus. Bioinformatics, 2011, 27, 3364-3370.	1.8	18
21	HIV-1 targeting of IFN regulatory factors. Future Virology, 2011, 6, 1397-1405.	0.9	7
22	Human Papillomavirus Type 16 E5 Protein Induces Expression of Beta Interferon through Interferon Regulatory Factor 1 in Human Keratinocytes. Journal of Virology, 2011, 85, 5070-5080.	1.5	24
23	Interferon regulatory factor-1 acts as a powerful adjuvant in DNA based vaccination. Journal of Cellular Physiology, 2010, 224, 702-709.	2.0	27
24	Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5. Journal of Cellular Physiology, 2009, 221, 760-765.	2.0	1
25	IRF-1 is required for full NF- $\kappa$ B transcriptional activity at the HIV-1 LTR enhancer. Cytokine, 2008, 43, 284.	1.4	0
26	IRF-1 Is Required for Full NF- $\kappa$ B Transcriptional Activity at the Human Immunodeficiency Virus Type 1 Long Terminal Repeat Enhancer. Journal of Virology, 2008, 82, 3632-3641.	1.5	83
27	IRF-7: New Role in the Regulation of Genes Involved in Adaptive Immunity. Annals of the New York Academy of Sciences, 2007, 1095, 325-333.	1.8	24
28	A requirement for NF- $\kappa$ B induction in the production of replication-competent HHV-8 virions. Oncogene, 2004, 23, 5770-5780.	2.6	38
29	Analysis of the Signal Transduction Pathway Leading to Human Immunodeficiency Virus-1-Induced Interferon Regulatory Factor-1 Upregulation. Annals of the New York Academy of Sciences, 2004, 1030, 187-195.	1.8	11
30	Role of Acetylases and Deacetylase Inhibitors in IRF-1-Mediated HIV-1 Long Terminal Repeat Transcription. Annals of the New York Academy of Sciences, 2004, 1030, 636-643.	1.8	31
31	On the Role of Interferon Regulatory Factors in HIV-1 Replication. Annals of the New York Academy of Sciences, 2003, 1010, 29-42.	1.8	16
32	Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene, 2003, 22, 964-973.	2.6	48
33	Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. Journal of Interferon and Cytokine Research, 2002, 22, 27-37.	0.5	43
34	Modulation of Human Immunodeficiency Virus 1 Replication by Interferon Regulatory Factors. Journal of Experimental Medicine, 2002, 195, 1359-1370.	4.2	102
35	HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene, 2001, 20, 800-811.	2.6	198